Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
A new analysis of the study yielded mixed news for black women, confirming that they suffer worse outcomes, even with the same genetic test results and treatment.
In the I-SPY 2 trial, investigators analyzed whether MammaPrint scores and BluePrint subtypes could help identify patients who would respond better to treatments.
The company attributed the growth to increasing global demand for breast cancer testing, and growing demand and reimbursement for its prostate test.
Palmetto proposes to cover the assay for prostate cancer patients who are at very low and low risk of negative outcomes with active surveillance by NCCN guidelines.
The company hopes to use proceeds from the stock offering to support the commercial launch of its Digital Spatial Profiling platform next year.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
The company plans to commercialize a gene expression signature to predict recurrence risk in cutaneous squamous cell carcinoma.
The company's net loss climbed about 30 percent to $4.0 million for Q4 2017, and reached $19.4 million for the full year.
The company plans to launch an RNA sequencing-based test to help subtype and determine treatment for thyroid cancer, and a test to detect noninvasive lung cancer.